Comparative Pharmacology
Head-to-head clinical analysis: AVELOX IN SODIUM CHLORIDE 0 8 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVELOX IN SODIUM CHLORIDE 0 8 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
400 mg intravenously once daily. Infuse over 60 minutes.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Terminal elimination half-life of moxifloxacin is approximately 11-15 hours in patients with normal renal function; allows once-daily dosing.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Renal (approximately 45-60% as unchanged drug and metabolites); biliary/fecal (approximately 20-25% as unchanged drug and metabolites); total urinary and fecal recovery >95%.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte